Chile is the first country in Latin America to acquire the monoclonal antibody Nirsevimab to prevent Respiratory Syncytial Virus (RSV) as part of the 2024 Winter Campaign, which began on April 1, 2024. The use of this monoclonal antibody is one of the most impactful preventive measures for the pediatric population in our history. More info.

The immunization strategy considers two target groups